Well said, I agree and feel the same way.
Trying to look at it from the Company's perspective, they've provided the following formal guidance and they have notified us of the delays.
It's debatable whether or not it's appropriate for them to tell us the FDA's question(s) in an announcement but JC might provide more insight in the November call or briefing.
While they're not executing on guidance, they may as well get on a roll and beat the financial guidance
Ann: Form 8-K, page-130
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.74 |
Change
0.250(10.0%) |
Mkt cap ! $170.3M | |||
| Open | High | Low | Value | Volume |
| $2.56 | $2.78 | $2.56 | $2.148M | 794.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 911 | $2.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.75 | 7135 | 1 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.76 |
Change
0.250 ( 10.1 %) |
||||
| Open | High | Low | Volume | ||
| $2.59 | $2.78 | $2.59 | 31457 | ||
| Last updated 15.58pm 29/05/2024 ? | |||||
| AVH (ASX) Chart |